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Treatment Disadvantages
As stated by Nature Reviews Gastroenterology & Hepatology, more than
one million people in the United states and over two and a half million
people in Europe are presumed to have IBD.3
Ø Since the twentieth century, Ulcerative Colitis and Crohn’s Disease
has significantly increased in the western world.
Ø The prevalence in the Western world has now increased to 0.5% of the
entire population.4
Ø Recently, IBD has evolved into a global disease and its prevalence in
every continent continues to grow exponentially.
Fig 3. Steps taken for treatment of IBD and their disadvantages5
Based on scientific literature, IBD is a chronic disease that does not have
any treatments without considerable side effects. The purpose of the
proposed drug polymer complex pH sensitive delivery system is to
reduce inflammation of the GI tract in Ulcerative Colitis and Crohn’s
Disease. The complex formulation has been shown using the
nanoprecipitation method with specific stabilizer, polymers and drug.
The drug, polymer and solvent solution was added dropwise into a vial of 
stabilizer and water under constant stirring.
The drug being formulated a natural antioxidant and less damaging than 
the medications listed above. 
The nanoprecipitate method was utilized to form a drug polymer complex.
In future experimentation, this project contains optimizing the drug 
release from the polymer using the pH dissolution test, drug loading, 
drug coatings at a range of different pH of the GI tract for release at 
specific times, and mice studies.
Drug: Silymarin Polymers: RS100/S100, 3:1 
Solvents: Acetone/Ethanol, 7:3 Stabilizer: PVA
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Fig 4. FTIR analysis of Polymer-Drug 
complex using Silymarin, RS100 and S100
Fig 5. FTIR of Silymarin
Fig 6. FTIR of Eudragit polymer S100
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Ø Cramps, Abdominal Pain
Ø Blood in stool
Ø Diarrhea, Constipation, bloating
Ø Visceral Hypersensitivity
Ø Fever, fatigue
Ø Unintended weight loss
Ø Intestinal Inflammation
Crohn’s Disease and Ulcerative Colitis
are cumulatively known as
Inflammatory Bowel Disease (IBD),
they are distinguished by inflammation
in the gastrointestinal tract. A survey
from 2017 stated that 57% of IBD
patients were originally misdiagnosed,
since the symptoms can suggest many
things.1 Symptoms include2
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Fig 7. FTIR of Eudragit polymer RS100
